Clinical Database and Biobank of Patients With Gynecologic Neoplasms

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2010 by Huazhong University of Science and Technology.
Recruitment status was Recruiting

Sponsor:

Collaborators:

Zhejiang University

Hunan Province Tumor Hospital

Guangxi Medical University

Health Science Center of Xi’an Jiaotong University

Information provided by:

Huazhong University of Science and Technology

ClinicalTrials.gov Identifier:

NCT01267851

First received: December 28, 2010

Last updated: February 14, 2011

Last verified: December 2010

History of Changes

Purpose

The database and biobank establishment started in 1997 in our institute. However, the sample size was too small with respect to our clinical and fundamental scientific research's requirement. Thus the Chinese gynecological oncology study (GOS) group was established to create a large multicentre database and biobank of patients with gynecologic diseases.

Condition
Cervical Cancer Ovarian Cancer Endometrial Cancer Choriocarcinoma Uterine Fibroids Endometriosis


Study Type:	Observational
Official Title:	A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms

Resource links provided by NLM:

Genetics Home Reference related topics: ovarian cancer

MedlinePlus related topics: Cancer

Genetic and Rare Diseases Information Center resources: Ovarian Cancer Choriocarcinoma

U.S. FDA Resources

Further study details as provided by Huazhong University of Science and Technology:


Study Start Date:	January 1999

Detailed Description:

The database contains clinical and epidemiologic information about patients with gynecologic neoplasms, such as cervical carcinoma, ovarian carcinoma, etc. With the data gathered from this database, the investigators could further demonstrate the etiology, risk factor, clinical treatment, and other aspects of the complicated gynecologic diseases. The cervical cancer database v1.10 including more than 10,000 cases and more than 200 variables has been established.

The biobank collects blood, fluids, tissue samples, and related clinical data from consenting patients with gynecologic neoplasms, such as cervical cancer, ovarian cancer, endometrial cancer, choriocarcinoma, uterine myoma, endometriosis. Besides, blood samples of population-based healthy people with informed consent are also collected.

Eligibility


Ages Eligible for Study:	18 Years to 75 Years (Adult, Senior)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

gynecologic diseases, such as cervical cancer, ovarian cancer, endometrial cancer, choriocarcinoma, uterine myoma, endometriosis, as well as part of population-based healthy women

Criteria

Inclusion Criteria:

patients with informed consent;
patients with gynecologic diseases;
patients with intact clinical and pathological information

Exclusion Criteria:

not included in the inclusion criteria

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01267851

Contacts


Contact: Ma Ding, M.D.	86-27-8362681	dma@tjh.tjmu.edu.cn

Locations


China, Hubei
Tongji Hospital of HUST	Recruiting
Wuhan, Hubei, China
Contact: Ma Ding, M.D. 86-27-8362681 dma@tjh.tjmu.edu.cn

Sponsors and Collaborators

Huazhong University of Science and Technology

Zhejiang University

Hunan Province Tumor Hospital

Guangxi Medical University

Health Science Center of Xi’an Jiaotong University

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hu T, Li S, Chen Y, Shen J, Li X, Huang K, Yang R, Wu L, Chen Z, Jia Y, Wang S, Cheng X, Han X, Lin Z, Xing H, Qu P, Cai H, Song X, Tian X, Xu H, Xu J, Zhang Q, Xi L, Deng D, Wang H, Wang S, Lv W, Wang C, Xie X, Ma D. Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria. Eur J Cancer. 2012 Oct;48(15):2353-60. doi: 10.1016/j.ejca.2012.03.015. Epub 2012 Apr 13.


Responsible Party:	Ding Ma, Cancer Biology Research Center of Tongji Hospital
ClinicalTrials.gov Identifier:	NCT01267851 History of Changes
Other Study ID Numbers:	GM2010-06-02
Study First Received:	December 28, 2010
Last Updated:	February 14, 2011
Health Authority:	China: Ministry of Health

Keywords provided by Huazhong University of Science and Technology:


gynecologic disease

Additional relevant MeSH terms:


Genital Diseases, Female Neoplasms Uterine Cervical Neoplasms Endometrial Neoplasms Endometriosis Leiomyoma Myofibroma Choriocarcinoma Genital Neoplasms, Female Uterine Neoplasms Urogenital Neoplasms Neoplasms by Site Uterine Cervical Diseases	Uterine Diseases Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms, Connective Tissue Connective Tissue Diseases Trophoblastic Neoplasms Neoplasms, Germ Cell and Embryonal Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Pregnancy Complications, Neoplastic Pregnancy Complications

ClinicalTrials.gov processed this record on September 26, 2016

To Top